ArticleInfluenza and other respiratory viruses2017
Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.
Article in Influenza and other respiratory viruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Immune Dysregulation in Down Syndrome: Implications for Infectious Susceptibility and Vaccine Response.Journal of clinical immunology · 2026Review
- How I Treat: Immune dysregulation in Down syndrome.Journal of human immunity · 2026Review
- RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.Vaccines · 2026Review
- Article
- Childhood infections and autism spectrum disorders and/or intellectual disability: a register-based cohort study.Journal of neurodevelopmental disorders · 2022Article
- The Potential Prognostic, Diagnostic and Therapeutic Targets for Recurrent Arrhythmias in Patients with Coronary Restenosis and Reocclusions After Coronary Stenting.Current pharmaceutical design · 2022Article
- Respiratory Syncytial Virus-Associated Hospitalizations in Children With Neurological Disorders, 2006-2015.Journal of the Pediatric Infectious Diseases Society · 2021Article
- Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence.Journal of inflammation research · 2021Review
- Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand.Influenza and other respiratory viruses · 2021Article
- Respiratory Syncytial Virus-related Death in Children With Down Syndrome: The RSV GOLD Study.The Pediatric infectious disease journal · 2020Article
- Immune Dysregulation in Children With Down Syndrome.Frontiers in pediatrics · 2020Review
- Pediatric intensive care unit admission due to respiratory syncytial virus: Retrospective multicenter study.Pediatrics international : official journal of the Japan Pediatric Society · 2019Article
- Palivizumab use in infants with Down syndrome-report from the German Synagis™ Registry 2009-2016.European journal of pediatrics · 2018Observational
- Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Human vaccines & immunotherapeutics · 2017Review
- Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases.Infectious diseases and therapy · 2017Review
- Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.Influenza and other respiratory viruses · 2017Article
- Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) infection in childhood, particularly in premature infants, is associated with significant morbidity and mortality.
objectivesTo compare the hospitalization rates due to RSV infection and severity of disease between infants with and without Down syndrome (DS) born at term and without other associated risk factors for severe RSV infection. PATIENTS/
methodsIn a prospective multicentre epidemiological study, 93 infants were included in the DS cohort and 68 matched by sex and data of birth (±1 week) and were followed up to 1 year of age and during a complete RSV season.
resultsThe hospitalization rate for all acute respiratory infection was significantly higher in the DS cohort than in the non-DS cohort (44.1% vs 7.7%, P<.0001). Hospitalizations due to RSV were significantly more frequent in the DH cohort than in the non-DS cohort (9.7% vs 1.5%, P=.03). RSV prophylaxis was recorded in 33 (35.5%) infants with DS. The rate of hospitalization according to presence or absence of RSV immunoprophylaxis was 3.0% vs 15%, respectively.
conclusionsInfants with DS showed a higher rate of hospitalization due to acute lower respiratory tract infection and RSV infection compared to non-DS infants. Including DS infants in recommendations for immunoprophylaxis of RSV disease should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.